Skip to content

Application of GeneXpert on Bronchoscopic Samples for Patients Suspicious of TB

Status
Completed
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT02838641
Enrollment
219
Registered
2016-07-20
Start date
2015-11-30
Completion date
2017-04-30
Last updated
2019-04-17

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Observation

Brief summary

This is an observational study using Bronchial-alveolar lavage (BAL) as specimen for GeneXpert, a real time polymerase chain reaction (PCR) test for detection of tuberculosis (TB). Patients suspicious of TB, who require bronchoscopy as part of the investigation procedures, will be recruited for this study over a period of 18 months. Clinical likelihood of TB will be systematically scored according to various clinical parameters. This will determine the pre-test probability. Clinician will decide if anti-TB treatment is to be started and patients will be followed up for a minimal of 18 months. Sensitivity, specificity, positive, negative predictive values and the respective likelihood ratio will be calculated accordingly.

Interventions

DEVICEGeneXpert

Real time integrated and automated nucleic acid amplification test for detection of TB

Sponsors

Chinese University of Hong Kong
Lead SponsorOTHER

Study design

Observational model
CASE_ONLY
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
ALL
Healthy volunteers
No

Inclusion criteria

1. Patients \> 18 years old suspected of TB clinically. 2. Patients suspected of TB but both smear microscopy and TB PCR of sputum are negative or sputum cannot be produced. 3. BAL samples obtained following standard investigation procedure 4. CXR or CT imaging available.

Exclusion criteria

1. Bronchoscopy is not planned as a necessary procedure for investigation. 2. Diagnosis of active TB has been made by other means.

Design outcomes

Primary

MeasureTime frame
sensitivity, specificity, positive and negative predictive values18 months

Countries

Hong Kong

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026